NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australia.
Hum Reprod. 2010 Apr;25(4):924-31. doi: 10.1093/humrep/dep418. Epub 2010 Jan 26.
The increase in use and costs of assisted reproductive therapies including in-vitro fertilization (IVF) has led to debate over public funding. A decision analytic model was designed to estimate the incremental cost-effectiveness of IVF by additional treatment programmes and maternal age.
Data from the Australian and New Zealand Assisted Reproductive Database were used to estimate incremental effects (live birth and other pregnancy outcomes) and costs for cohorts of women attempting up to three treatment programmes. A treatment programme included one fresh cycle and a variable number of frozen cycles dependent on maternal age.
The incremental cost per live birth ranged from AU dollars 27 373 and AU dollars 31 986 for women aged 30-33 on their first and third programmes to AU dollars 130 951 and AU dollars 187 515 for 42-45-year-old women on their first and second attempts. Overall, these trends were not affected by inclusions of costs associated with ovarian hyperstimulation syndrome or multiple births.
This study suggests that cost per live birth from IVF increases with maternal age and treatment programme number and indicates that maternal age has the much greater effect. This evidence may help decisionmakers target the use of IVF services conditional on societal willingness to pay for live births and equity considerations.
辅助生殖技术(包括体外受精[IVF])的使用和成本增加引发了关于公共资金的争论。设计了一个决策分析模型,以估计通过额外的治疗方案和产妇年龄来评估 IVF 的增量成本效益。
使用澳大利亚和新西兰辅助生殖数据库的数据来估计最多进行三次治疗方案的女性队列的增量效果(活产和其他妊娠结局)和成本。一个治疗方案包括一个新鲜周期和取决于产妇年龄的可变数量的冷冻周期。
对于 30-33 岁的女性,第一个和第三个治疗方案的每活产增量成本分别为 27373 澳元和 31986 澳元,对于 42-45 岁的女性,第一个和第二个尝试的每活产增量成本分别为 130951 澳元和 187515 澳元。总体而言,这些趋势不受与卵巢过度刺激综合征或多胎妊娠相关成本的影响。
本研究表明,IVF 的每活产成本随着产妇年龄和治疗方案数量的增加而增加,并表明产妇年龄的影响更大。这一证据可能有助于决策者根据社会对活产的支付意愿和公平性考虑,有条件地利用 IVF 服务。